Julien Rongère

General Counsel at AC IMMUNE SA

47 year

Health Technology

Consumer Services

Profile

Julien Rongère is currently working as the VP-Regulatory Affairs & Quality Assurance at AC Immune SA. Previously, he worked as the Director-Regulatory Affairs at Celgene Switzerland SARL and as a Regulatory Expert at Apoxis SA. Dr. Rongère holds a graduate degree from the University of Aberdeen and a doctorate degree from the University of Lausanne.

Julien Rongère active positions

Companies	Position	Start
AC IMMUNE SA	General Counsel	2017-06-30

All active positions of Julien Rongère

Former positions of Julien Rongère

Companies	Position	End
Apoxis SA Apoxis SA Pharmaceuticals: MajorHealth Technology Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland.	Corporate Officer/Principal	-
Celgene Switzerland SARL Celgene Switzerland SARL Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Switzerland SARL is a Swiss biopharmaceutical company. The private company is based in Boudry, Switzerland.	General Counsel	-

See the detail of Julien Rongère's experience

Training of Julien Rongère

University of Aberdeen	Graduate Degree
University of Lausanne	Doctorate Degree

Experiences
Positions held

Active

Inactive

Listed companies

Private companies

See the detail of Julien Rongère's experience

Connections

1st degree connections

1st degree companies

Male

Female

Members of the board

Executives

See the personal network

Linked companies

Listed companies	1
AC IMMUNE SA	Health Technology

Private companies	2
Apoxis SA Apoxis SA Pharmaceuticals: MajorHealth Technology Apoxis SA develops therapeutics for the treatment of cancer and immunological diseases based on the mechanisms underlying apoptosis or cell death. The company particularly focuses on diseases with unmet medical needs and high commercial potential. It's lead product, APO866, is a novel small molecule therapeutic for the treatment of a range of cancers. The product is also being evaluated in a range of cancers in combination with commonly used chemo and radiotherapies in preclinical studies. It's oncology portfolio also includes APO010, a protein therapeutic that was developed using the company’s proprietary multimerization technology. The company is headquartered in Lausanne, Switzerland.	Health Technology
Celgene Switzerland SARL Celgene Switzerland SARL Pharmaceuticals: MajorHealth Technology Part of Bristol Myers Squibb Co., Celgene Switzerland SARL is a Swiss biopharmaceutical company. The private company is based in Boudry, Switzerland.	Health Technology